- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: Minnesota Legislator Discusses Bill to Broaden Biosimilar Coverage
State Representative Jennifer Schultz (D, Duluth) explains how her bill requiring payers to cover all approved biosimilars and reference products would save money and improve access.
Recently, legislators in Minnesota introduced a bill that could force health plans and pharmacy benefit managers (PBMs) to provide equal coverage for biosimilars and reference products, removing the ability for plans to prefer higher-cost originators or limited numbers of biosimilars. The bipartisan bill was designed by Representative Jennifer Schultz (D, Duluth) and Senator Carla Nelson (R, Rochester) and was drafted in consultation with research scientists at Essentia Health and the Mayo Clinic.
We spoke with Schultz, who has a PhD in health economics, to discuss why a bill like this is needed in Minnesota and how it can help foster competition in the biologics market.
To learn more about the bill, click here.
To read the bill’s official text, click here.
To learn more about payer formulary preferences, click here.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
British Columbia’s Biosimilar Policy Shows No Impact on Hospital Visits
May 28th 2025Despite a dramatic shift toward biosimilar use following British Columbia’s policy, researchers found no rise in hospital visits or complications, underscoring the real-world reliability of etanercept biosimilars in managing inflammatory arthritis.
